Condition: Uncontrolled Hypertension · Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
The purpose of this study is to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of SAL0140 healthy Chinese population.
This description comes directly from the study's public registry record.
Chongyuan Xu, Ph.D. · 13926186470 · nflcyljd@smu.edu.cn
Always discuss trial participation with your own doctor first.
| Nanfang Hospital of Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07051603